G1 Therapeutics, Inc and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States
What does Early Access actually mean?
Naomi Litchfield, Patient Advocacy Manager for Bionical Emas, discusses the basic principles of Early Access Programs
Four things to think about: PVG in EAPs
By Nisha Vora - Senior Project Manager, Pharmacovigilance